Smith+Nephew After the CFO Exit: What the Turnaround Numbers Say

Smith+Nephew lost about 3.5% of its value on 19 August, taking the shares to roughly 1,071.84p and putting it among the largest fallers in the FTSE 100, after it announced that chief financial officer John Rogers had resigned. He steps down from the board with immediate effect, leaves the company on 30 September and starts as executive vice president and chief financial officer of Baxter International on 1 October. On a group capitalised at around £9.3bn, that is roughly £325m of value attributed to the departure of one executive.

Nobody genuinely believes one CFO is worth £325m. What the market was marking down is execution certainty on a turnaround that is two years in, still incomplete, and whose credibility rests almost entirely on margin targets the departing CFO personally owned and defended. Anyone looking at the Smith+Nephew share forecast should start from that distinction: the guidance itself has not changed since the half-year results, and the numbers underneath it are running better than the revenue line suggests. What has changed is who is accountable for delivering the second half of the plan, and the fact that no permanent successor has been named.

What actually happened

Rogers had been CFO since 2024, having joined as CFO-designate the year before. Pierre Palassian, senior vice president finance and group controller, has been appointed interim CFO while a search for a permanent successor is under way. Three details in the announcement are worth more than the headline.

First, the immediacy. Rogers left the board on the day of the announcement rather than on his last day of employment, which is 30 September. A finance director who remains employed for six weeks but is off the board from day one is not running a handover in the normal sense.

Second, the terms. Smith+Nephew said Rogers remains employed until 30 September on normal salary, benefits and pension terms, with no severance payment, and that his outstanding incentive awards lapse. That is the correct treatment for a voluntary resignation and it tells you this was a resignation to take a bigger job, not a managed exit. It also means he walks away from unvested awards tied to the very margin targets the market is now questioning.

Third, the destination. Baxter hired him explicitly to help advance its own turnaround. The medtech turnaround skill set is scarce and the market for it is competitive, which is context that cuts slightly in Smith+Nephew's favour on the quality of what it built, and firmly against it on retention.

Why the market reacted the way it did

The reaction only makes sense in the context of results published a fortnight earlier, on 4 August.

Those results were not bad. For the half year to 27 June, revenue was $3.097bn, up 2.3% underlying and 4.6% reported. Trading profit rose 8.1% on a reported basis to $566m. Trading profit margin improved 60 basis points to 18.3%. Orthopaedics — the franchise at the centre of every bear case on this company for a decade — improved its margin to 13.0% from 12.7%. Chief executive Deepak Nath credited the 12-Point Plan with making the group resilient enough to convert a soft top line into a good profit outcome.

But the top line was soft. Second-quarter underlying revenue growth was 1.6%, which the company itself called lower than expected, with strength in Sports Medicine offset by weakness in US Orthopaedics and Advanced Wound Bioactives. Management trimmed full-year underlying revenue growth guidance to around 4% from around 6%, while maintaining every other metric: roughly 8% trading profit growth, around $800m of free cash flow, and adjusted return on invested capital above 10%. It funded that hold by raising its efficiency savings target for the year to $200m from $150m, having found additional manufacturing and procurement gains, and by tariff refunds that fully offset the forecast tariff headwind.

That is the setup the CFO exit landed into. The company had just told the market it would deliver unchanged profit and cash on materially lower revenue, by finding an extra $50m of savings. It is an entirely legitimate answer — but it is a promise that runs through the finance function, and it was made by the person who then resigned two weeks later. The share price move was not about losing an executive. It was about the market reweighting the probability attached to a self-help number.

The Openbook read

Profitability is the load-bearing factor here and it is genuinely improving, which is the part of this story most coverage skipped. An 18.3% trading margin, up 60 basis points, with Orthopaedics up 30 basis points to 13.0%, is real reported progress rather than guidance. The 8.1% trading profit growth against 2.3% underlying revenue growth is the clearest single expression of the 12-Point Plan working: roughly six points of margin-driven profit growth on top of volume. The caveat is composition. When part of that gap is filled by an efficiency programme raised mid-year and by tariff refunds, the quality of the beat is lower than the size of it, and the recurring rate of improvement is the number that matters rather than the reported one.

Growth is the weak factor and the guidance cut confirms it. Around 4% underlying growth for the full year, with a second quarter at 1.6%, is below the medtech peer group and below what a business with this asset base should be capable of. Sports Medicine is growing well, with REGENETEN and FASTSEAL named as drivers. US Orthopaedics is not. Growth here is a franchise-mix problem, and a mix problem has a structural answer that a cost programme cannot supply.

Momentum is mixed rather than broken, and needs flagging as such. The 3.5% fall came after a period in which the shares had absorbed a revenue downgrade without collapsing. Earnings-revision momentum is arguably better than price momentum, because the profit line has been revised up while the revenue line was revised down — an unusual and informative combination.

Solvency is comfortable and is the reason the turnaround has time to run. The group guided to around $800m of free cash flow for the year, raised its interim dividend by 4%, and is executing a $500m buyback of which $216m had been completed by 3 August. A company running a buyback of that size alongside a dividend increase is not one whose balance sheet constrains the plan. Adjusted ROIC above 10% is the relevant discipline to watch rather than leverage.

Reward/Risk is where the exit genuinely changes something, because of who else is on the register. Cevian Capital has been building steadily all year — from just over 10% in May to 11.01% on 11 May, 12.07% on 8 June, 14.01% on 22 July and 14.21% by 7 August. An activist holding better than one share in seven, a sum-of-the-parts discount that has not closed, an incomplete margin programme and now a vacant finance seat is a combination that tends to increase the volume of the structural argument rather than reduce it. Whether that resolves as portfolio separation, a listing debate or simply more pressure on the existing plan is unknowable from here. What is knowable is that the range of outcomes has widened in both directions, which is precisely what a reward/risk score is meant to capture. The full factor breakdown sits on the Smith+Nephew profile.

The read-across

The first read-across is to Baxter, which has acquired a CFO with two years of live experience running exactly the kind of margin recovery Baxter needs. For anyone following Baxter International, this is a more meaningful hire than a routine finance appointment, and the market treated it as such on both sides of the Atlantic.

The second is to the orthopaedics complex. Smith+Nephew's specific weakness was US Orthopaedics rather than the franchise globally, which matters for how Stryker, Zimmer Biomet and Johnson & Johnson MedTech read the datapoint. A single-company US ortho shortfall against a growing sports medicine line points at competitive position and salesforce execution rather than a procedure-volume downturn — the market has spent two years worrying about the latter, and this is not evidence for it.

The third is thematic, and it is the one UK investors should care about most. Smith+Nephew is a British-listed company with a heavily American revenue base, an American-dominated peer group, an activist pressing for structural change, and now a CFO who left for a US employer. That is the UK listing discount argument in a single announcement. It says nothing definitive about what the company will do, but it is another data point in a pattern that has been running across the FTSE 100 for several years. Comparable UK-listed healthcare names can be screened side by side through the Openbook screener.

What to watch next

• 30 September and 1 October. Rogers leaves Smith+Nephew on 30 September and starts at Baxter the following day. Pierre Palassian is interim from now.
• The permanent appointment. The single most informative signal available. An internal promotion suggests continuity of the 12-Point Plan; an external hire with restructuring or separation experience suggests something else. The length of the search matters as much as the choice.
• The 4% revenue guide. Full-year underlying growth of around 4% now requires a second-half acceleration from a second quarter that ran at 1.6%. That is the number that determines whether the profit guide holds without further cost offsets.
• The $200m efficiency target. Raised from $150m mid-year. Delivery against it is what protects the roughly 8% trading profit growth guide, and it is the first thing an interim CFO inherits.
• Cevian's filings. The stake has moved from around 10% to 14.21% between May and early August. Further disclosures, or the absence of them, will say more about the structural case than any broker note.
• The remaining buyback. Roughly $284m of the $500m programme was outstanding as at 3 August. The pace of execution from here is a readable signal about management's own confidence in the cash guide.